MOESM2 of The PPAR-γ antagonist T007 inhibits RANKL-induced osteoclastogenesis and counteracts OVX-induced bone loss in mice

Additional file 2: Figure S2. A simplified model of the mechanism by which T007 inhibits osteoclastogenesis and osteoblastogenesis. T007 reduces PPARγ expression that inhibits osteoclast progenitor’s differentiation into osteoclasts, thus attenuating bone resorption. In osteoclast progenitor, T007 suppress c-Fos expression, which stimulates osteoclastogenesis. Conversely, T007 restrains PPARγ activation that promotes pre-osteoblasts differentiation into osteoblasts and contributes to BMSCs growth by increasing Runx2 expression, thus enhancing bone formation. Consequently, T007 results in bone loss by tipping in balance of bone remodeling through concerned stimulation of bone resorption and inhibition of bone formation.